Harbin Pharmaceutical Group (600664) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

CN Stock MarketDetailed Quotes

600664 Harbin Pharmaceutical Group

Watchlist

3.87
+0.07+1.84%

Not Open Jan 15 15:00 CST

9.75BMarket Cap15.93P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Harbin Pharmaceutical Group Co., Ltd.'s (SHSE:600664) Business And Shares Still Trailing The Market
Simply Wall StDec 30, 2024 21:35 ET
Harbin Pharmaceutical Group (SHSE:600664) Strong Profits May Be Masking Some Underlying Issues
Simply Wall StNov 1, 2024 18:15 ET
These 4 Measures Indicate That Harbin Pharmaceutical Group (SHSE:600664) Is Using Debt Safely
Simply Wall StOct 9, 2024 01:40 ET
Shareholders in Harbin Pharmaceutical Group (SHSE:600664) Have Lost 26%, as Stock Drops 5.0% This Past Week
Simply Wall StSep 12, 2024 19:31 ET
There's No Escaping Harbin Pharmaceutical Group Co., Ltd.'s (SHSE:600664) Muted Earnings Despite A 25% Share Price Rise
Simply Wall StAug 8, 2024 18:55 ET
China Grants Harbin Pharmaceutical's Supplementary Drug Application for Antibiotic
MT NewswiresAug 8, 2024 05:15 ET

Comments

Moomoo AI

Feb 5, 2024 18:15

Harbin Pharmaceutical Group's low P/S ratio may indicate anticipated poor growth or falling revenue, underperforming the industry. The company's recent revenue trends, worse than industry expectations, contribute to its low P/S. Shareholders accept this, expecting no future revenue surprises. Unless medium-term conditions improve, they will continue to hinder the share price.

Investors Don't See Light At End Of Harbin Pharmaceutical Group Co., Ltd.'s (SHSE:600664) Tunnel And Push Stock Down 26%

Moomoo AI

Dec 19, 2023 19:50

Low P/S ratio suggests investors think company's growth may not keep up with the industry. Recent revenue trends imply the share price may not rise soon. Investors should beware of a specific warning for the company.

Lacklustre Performance Is Driving Harbin Pharmaceutical Group Co., Ltd.'s (SHSE:600664) Low P/S

Moomoo AI

Oct 19, 2023 19:03

Market might be less excited about Harbin Pharmaceutical Group hinting at a possible buying opportunity. The company's five-year annualised TSR loss signals caution for potential investors.